141 related articles for article (PubMed ID: 35085661)
1. Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.
Bui AD; Kong CL; Kelly NK; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan B; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Acharya NR;
Ophthalmology; 2022 Jun; 129(6):721-723. PubMed ID: 35085661
[No Abstract] [Full Text] [Related]
2. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.
Rathinam SR; Babu M; Thundikandy R; Kanakath A; Nardone N; Esterberg E; Lee SM; Enanoria WT; Porco TC; Browne EN; Weinrib R; Acharya NR
Ophthalmology; 2014 Oct; 121(10):1863-70. PubMed ID: 24917273
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
Sobrin L; Christen W; Foster CS
Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis.
Al-Khersan H; Fowler BJ; Clauss KD; Kunkler AL; Yannuzzi NA; Patel NA; Sridhar J; Albini TA; Smiddy WE
Ophthalmol Retina; 2021 Dec; 5(12):1281-1282. PubMed ID: 34411777
[No Abstract] [Full Text] [Related]
6. A Bayesian Analysis of a Randomized Clinical Trial Comparing Antimetabolite Therapies for Non-Infectious Uveitis.
Browne EN; Rathinam SR; Kanakath A; Thundikandy R; Babu M; Lietman TM; Acharya NR
Ophthalmic Epidemiol; 2017 Feb; 24(1):63-70. PubMed ID: 27982726
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.
Tsui E; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Balamurugan S; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan J; Ebert CD; Kim E; Madow B; Porco TC; Acharya NR;
Ophthalmology; 2022 Jun; 129(6):661-667. PubMed ID: 35143800
[TBL] [Abstract][Full Text] [Related]
8. Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?
Jabs DA
JAMA Ophthalmol; 2019 Dec; 137(12):1449-1451. PubMed ID: 31503274
[No Abstract] [Full Text] [Related]
9. Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases.
Gangaputra SS; Newcomb CW; Joffe MM; Dreger K; Begum H; Artornsombudh P; Pujari SS; Daniel E; Sen HN; Suhler EB; Thorne JE; Bhatt NP; Foster CS; Jabs DA; Nussenblatt RB; Rosenbaum JT; Levy-Clarke GA; Kempen JH;
Am J Ophthalmol; 2019 Dec; 208():68-75. PubMed ID: 31344346
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
Kong CL; Kelly NK; Sundararajan M; Rathinam SR; Gonzales JA; Thundikandy R; Vedhanayaki R; Kanakath A; Murugan B; Doan T; Goldstein D; Al-Dhibi HA; Acharya NR
Ocul Immunol Inflamm; 2022 Jan; 30(1):198-202. PubMed ID: 32779952
[TBL] [Abstract][Full Text] [Related]
11. Rescue therapy with mycophenolate mofetil in refractory uveitis.
Kilmartin DJ; Forrester JV; Dick AD
Lancet; 1998 Jul; 352(9121):35-6. PubMed ID: 9800750
[No Abstract] [Full Text] [Related]
12. Mycophenolate mofetil therapy.
Kilmartin DJ; Dick AD
Ophthalmology; 1999 Sep; 106(9):1645. PubMed ID: 10485526
[No Abstract] [Full Text] [Related]
13. Mycophenolate mofetil therapy for inflammatory eye disease.
Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil use in the treatment of noninfectious uveitis.
Klisovic DD
Dev Ophthalmol; 2012; 51():57-62. PubMed ID: 22517204
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
[TBL] [Abstract][Full Text] [Related]
16. [Immunosuppressive therapy in severe or chronic pediatric uveitis: Review of the literature].
Stolowy N; Zanin E; Comet A; Jurquet AL; Benso C; Matonti F; Retornaz K; Kaplanski G; Denis D
J Fr Ophtalmol; 2021 Feb; 44(2):252-258. PubMed ID: 33423814
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation.
Lau CH; Comer M; Lightman S
Clin Exp Ophthalmol; 2003 Dec; 31(6):487-91. PubMed ID: 14641155
[TBL] [Abstract][Full Text] [Related]
18. The first case of sarcoidosis treated with mycophenolate mofetil.
Altschuler EL
Br J Dermatol; 2003 Aug; 149(2):442; discussion 442-3. PubMed ID: 12932272
[No Abstract] [Full Text] [Related]
19. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Deuter C
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1235-43. PubMed ID: 21720813
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil and methotrexate efficacy in dermatomyositis.
Grinnell M; Keyes E; Diaz D; Vazquez T; Feng R; Werth VP
Br J Dermatol; 2022 Sep; 187(3):437-438. PubMed ID: 35257367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
